(Q34982289)

5 August 2017

1 reference

title

Alzheimer's disease: treatments in discovery and development (English)

1 reference

5 August 2017

0 references

Martin Citron

1

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 November 2002

1 reference

5 August 2017

1 reference

5 August 2017

volume

5 Suppl

1 reference

5 August 2017

page(s)

1055-1057

1 reference

Baylor profound mental status examination: a brief staging measure for profoundly demented Alzheimer disease patients.

5 August 2017

cites work

1 reference

7 January 2021

Amyloid deposition as the central event in the aetiology of Alzheimer's disease

1 reference

7 January 2021

The role of A beta 42 in Alzheimer's disease

1 reference

7 January 2021

Translating cell biology into therapeutic advances in Alzheimer's disease

1 reference

7 January 2021

Protease inhibitors: current status and future prospects

1 reference

7 January 2021

aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation

1 reference

7 January 2021

gamma-Secretase, Notch, Abeta and Alzheimer's disease: where do the presenilins fit in?

1 reference

7 January 2021

Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE

1 reference

7 January 2021

Structure of the protease domain of memapsin 2 (beta-secretase) complexed with inhibitor

1 reference

7 January 2021

Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation

1 reference

7 January 2021

Purification and cloning of amyloid precursor protein beta-secretase from human brain

1 reference

7 January 2021

Transgenic mouse models of Alzheimer's disease

1 reference

7 January 2021

Plaque busters: strategies to inhibit amyloid formation in Alzheimer's disease

1 reference

7 January 2021

Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice.

1 reference

7 January 2021

The galvanization of beta-amyloid in Alzheimer's disease

1 reference

7 January 2021

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

1 reference

7 January 2021

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

1 reference

7 January 2021

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

1 reference

7 January 2021

Inflammation, autotoxicity and Alzheimer disease

1 reference

7 January 2021

A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity

1 reference

7 January 2021

Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.

1 reference

7 January 2021

Statins and the risk of dementia

1 reference

7 January 2021

Simvastatin strongly reduces levels of Alzheimer's disease beta -amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo

1 reference

7 January 2021

Cholesterol modulation as an emerging strategy for the treatment of Alzheimer's disease

1 reference

7 January 2021

Acyl-coenzyme A: cholesterol acyltransferase modulates the generation of the amyloid beta-peptide

1 reference

7 January 2021

Identifiers

DOI

10.1038/NN940

1 reference

5 August 2017

1 reference